Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALStandard

INVOKAMET XR

CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE

Standard Dose
150MG;500MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary

Approval overview INVOKAMET XR is listed in Drugs@FDA under application 205879 (NDA).

Review priority: PRIORITY Marketing status: Prescription Active ingredient CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE Form and strength TABLET, EXTENDED RELEASE;ORAL - 150MG;500MG Sponsor JANSSEN PHARMS Submission history Latest submission status date: 2024-12-18 00:00:00.

Structured Monograph

Clinical summary

Approval overview INVOKAMET XR is listed in Drugs@FDA under application 205879 (NDA). Review priority: PRIORITY Marketing status: Prescription Active ingredient CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE Form and strength TABLET, EXTENDED RELEASE;ORAL - 150MG;500MG Sponsor JANSSEN PHARMS Submission history Latest submission status date: 2024-12-18 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: PRIORITY

Interaction Notes

  • No interaction notes stored yet.